Mandate

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

July 19, 2024 M&A

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.

Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a EUR 600 million financing agreement with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.

The new facility of EUR 600 million is used to refinance Embracer’s existing revolving credit facilities of SEK 4.8 billion. The terms and conditions for the new facility have been improved, including a notably lower credit margin for utilised debt, which will reduce interest expenses through both improved terms and a reduced financial leverage.

Vinge’s team consisted of Albert Wållgren, Felix Möller, Ida Redander and Josef Groow.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026